Award Data

DESCRIPTIONprovided by applicantA joint DOE NCI workshop on ion beam therapyJanuaryBethesdaMDidentified an ambitious set of technology developments needed to support a world class treatment program for ion beam therapyOne important requirement is the ability to provide detectors that afford single particle registration at high data rates with hgh degree of uniformity and minimal interference with ...

DESCRIPTION provided by applicant Smoking kills Americans annually exacerbates myriad diseases and costs billions in healthcare and productivity losses Numerous barriers exist to accessing traditional treatment e g costs traveling to and scheduling appointments other logistics Text messaging is an extremely popular communication method Over of all Americans use text m ...

DESCRIPTION provided by applicant Navidea Biopharmaceuticals is seeking SBIR Fast Track grant support for preclinical animal studies and a regulatory phase clinical study of the ability of mTc tilmanocept to identify skeletal joint inflammation due to rheumatoid arthritis RA RA is a chronic progressive systemic autoimmune disease characterized by skeletal joint inflammation If not ...

DESCRIPTION provided by applicant The goal of this project is to provide a synthetic biomaterial capable of giving long term repair of full thickness chondral lesions with the aim of helping to reduce the joint replacements carried out each year in the USA Our company has developed a synthetic biomaterial technology with proven biocompatibility in treating over patients for bon ...

DESCRIPTION provided by applicant Hiltonol poly ICLC is a stabilized dsRNA therapeutic viral mimic or andapos danger signalandapos that activates multiple elements of innate and adaptive immunity It is a standalone immunomodulator but when properly combined with antigen it generates a comprehensive Th weighted immune response best suited for antiviral and antitumor action This project ...

DESCRIPTION provided by applicant Navidea Biopharmaceuticals has developed mTc tilmanocept as a radiopharmaceutical diagnostic imaging agent targeted to the macrophage mannose receptor CD to be used as an aid for lymphatic mapping in cancer surgeries The United States Food and Drug Administration approved Navideaandapos s new drug application NDA for mTc Tilmanocept for use in surge ...

Research conducted in Phase I identified a range of data sources providing vehicle related information to consumers shopping around or interested in knowing more about vehicles. Majority of the commercial data sources focused on vehicle features, new/used/CPO pricing, and vehicles listings. Such data sources lacked safety as their central focus, which is a concern for U.S. Department of Transporta ...

Project Summary. Dyad Medical, Inc. will create intravascular Optical Coherence Tomography (IVOCT) software for clinical, live time determination of stent apposition and for offline analysis of stent implantation. Every year, 100s of thousands of patients in the US are treated with intravascular stents creating an opportunity for both solutions. Although advancements such as drug eluting metal ste ...

PROJECT SUMMARY Glaucoma is an optic nerve disease in which there is progressive loss of retinal ganglion cells leading to irreversible loss of vision. It is estimated to affect 2% of the general population. More than 2.3 million Americans are affected with glaucoma and it is estimated to account for nearly $3B in direct medical costs. It is estimated that 4% of Caucasian patients and 8% of Africa ...

Project Summary/Abstract This SBIR Phase II project will advance the commercialization of our 3D guidance, navigation, and control (3D- GNC) system to improve stent-graft (SG) deployment during endovascular aortic aneurysm repair (EVAR) by overcoming limitations of 2D x-ray fluoroscopy (“fluoro”). 3D-GNC will increase safety, effectiveness, and efficiency as a result of better visualization, p ...